D&A
Johnson & Johnson D&A decreased by 0.3% to $2.00B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.1%, from $1.77B to $2.00B. Over 4 years (FY 2021 to FY 2025), D&A shows relatively stable performance with a 0.4% CAGR.
Analysis
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
depreciation_and_amortization_cfHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.84B | $1.81B | $1.84B | $1.77B | $1.74B | $1.69B | $1.77B | $1.88B | $1.93B | $1.83B | $1.84B | $1.82B | $1.78B | $1.85B | $1.90B | $1.77B | $1.94B | $1.78B | $2.01B | $2.00B |
| QoQ Change | — | -1.4% | +1.6% | -4.0% | -1.4% | -3.4% | +5.2% | +6.1% | +2.9% | -5.4% | +0.8% | -1.5% | -1.8% | +3.6% | +2.7% | -6.5% | +9.7% | -8.5% | +13.2% | -0.3% |
| YoY Change | — | — | — | — | -5.2% | -7.1% | -3.9% | +6.3% | +10.9% | +8.5% | +4.0% | -3.5% | -7.9% | +0.9% | +2.9% | -2.4% | +9.0% | -3.7% | +6.1% | +13.1% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $700.00M | $700.00M | $967.00M | $600.00M | $800.00M | $600.00M | $1.02B | $800.00M |
| MEDTECH | $400.00M | $500.00M | $867.00M | $500.00M | $500.00M | $500.00M | $926.00M | $500.00M |
| General Corporate | $126.00M | $96.00M | $62.00M | $52.00M | $60.00M | $59.00M | — | $65.00M |
| Consumer Health | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Total | $1.78B | $1.85B | $1.90B | $1.77B | $1.94B | $1.78B | $2.01B | $2.00B |
Consumer Health is derived from annual filings.
PHARMACEUTICAL was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's d&a?
- Johnson & Johnson (JNJ) reported d&a of $2.00B in Q1 2026.
- How has Johnson & Johnson's d&a changed year-over-year?
- Johnson & Johnson's d&a increased by 13.1% year-over-year, from $1.77B to $2.00B.
- What is the long-term trend for Johnson & Johnson's d&a?
- Over 4 years (2021 to 2025), Johnson & Johnson's d&a has grown at a 0.4% compound annual growth rate (CAGR), from $7.39B to $7.50B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.